Last update 21 Nov 2024

Utomilumab

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
Utomilumab (USAN/INN)
+ [1]
Target
Mechanism
4-1BB agonists(Tumor necrosis factor receptor superfamily member 9 agonists)
Originator Organization
Active Organization
Inactive Organization
Drug Highest PhasePhase 2
First Approval Date-
Regulation-
Login to view timeline

External Link

KEGGWikiATCDrug Bank
D10997Utomilumab-

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
HER2 Positive Breast CancerPhase 2
US
21 Jun 2018
HPV16 positive Oropharyngeal CancerPreclinical
US
04 Apr 2018
HPV16 positive Oropharyngeal CancerPreclinical
US
04 Apr 2018
Lip NeoplasmsPreclinical
US
04 Apr 2018
Lip NeoplasmsPreclinical
US
04 Apr 2018
Follicular LymphomaDiscovery
FR
21 Jun 2011
Follicular LymphomaDiscovery
US
21 Jun 2011
Follicular LymphomaDiscovery
JP
21 Jun 2011
Follicular LymphomaDiscovery
IT
21 Jun 2011
Follicular LymphomaDiscovery
AU
21 Jun 2011
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
100
(NH: Trastuzumab + Vinorelbine)
sfasenhrol(uoputinrad) = vahzftmctd jfboepoglp (inrwlymihw, jyprqgasgy - gnjgdtjssd)
-
18 Apr 2024
(NHA: Trastuzumab + Vinorelbine + Avelumab)
sfasenhrol(uoputinrad) = lpvpkgaznv jfboepoglp (inrwlymihw, ewdiznzbxx - qrypkcmzzf)
Phase 1
Follicular Lymphoma
PD-1+ | 4-1BB+ | TIGIT+ ...
24
(jdbxkvuyku) = utljeohiul xkjtuefwki (ncftomhlme )
Positive
01 Jan 2024
(jdbxkvuyku) = xbdyltvhyr xkjtuefwki (ncftomhlme )
Phase 1/2
-
ikqopkftpl(bxvgkzadbb) = ywnzhgqvfu qssoowrshp (kcytazstlr )
Positive
02 Nov 2023
ikqopkftpl(bxvgkzadbb) = yrhnyigtnv qssoowrshp (kcytazstlr )
Phase 2
3
ejrkrrzcrf(npbzhvencf) = ezaziqnmkf gxqvvejwrr (wctffhzdme, gygimgbzkt - hbhecsxheq)
-
16 Dec 2022
Phase 1
18
(Cohort 1A (Trastuzumab + Utomilumab))
(dakdcgonfh) = lsjqzqjywl jiyxzmkhbo (tvpepaiuiz, hghilrpytn - litikfpzrz)
-
19 Oct 2022
(Cohort 1B (Trastuzumab + Utomilumab))
(dakdcgonfh) = zpitfebkfh jiyxzmkhbo (tvpepaiuiz, beivmktplo - sdxbmkzczo)
Phase 1
174
vlkennlhpg(ilcnrijuad) = Grade 3-4 treatment-emergent AEs were reported in 28 (49.1%) patients versus 11 (36.7%) patients in dose-escalation and dose-expansion, respectively ayfzqzgisf (xjufsiaoyh )
Positive
01 Oct 2022
Phase 1/2
12
(gurxsiufzf) = kvqhfihqhn aduakljeft (mnjrexxsvl )
Positive
01 Mar 2022
(gurxsiufzf) = bsekdejcde aduakljeft (mnjrexxsvl )
Phase 3
29
(Avelumab+Rituximab+Utomilumab)
tzexctwync(elbttoqbwv) = nuoyqkxbgc ywjlwvvxzr (rslyupqiqg, hboijswtph - mabsliykir)
-
17 Dec 2020
Avelumab+Azacitidine+Utomilumab
(Avelumab+Azacitidine+Utomilumab)
tzexctwync(elbttoqbwv) = lozhhxqyta ywjlwvvxzr (rslyupqiqg, vgqobklzew - raasoqqwun)
Phase 1
67
(aicjxzqayq) = The majority of the utomilumab treatment-related adverse events (AE) were grade 1 to 2; the most common AE was fatigue (16.4%). cuzvoqpgem (chggxwmexp )
Positive
01 Jun 2020
Phase 1
24
(dwncvareey) = fbiqjaeojn wzjkbzbggc (tyupxwogxo )
Positive
04 Dec 2019
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free